We are pleased to announce that GeneFluidics has been selected as one of five finalists for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 by National Institute of Health (NIH). The main purpose of the Antimicrobial Resistance Rapid Challenge is to incentivize the development of in vitro diagnostic tests that […]
GeneFluidics, a molecular diagnostics company based in California and specializing in the development of diagnostics solutions for infectious diseases, today announced CE marking for UtiMax™ under the Directive 98/79/EC on in vitro diagnostic medical devices. The company’s new urine-to-result test has successfully completed a multicenter validation study and clinical testing. UtiMax™ […]
Irwindale, CA – September 10th,2015 – GeneFluidics Inc., a biotechnology company that specializes in designing and developing diagnostic systems that incorporate electrochemical-based molecular analysis and lab automation platforms, today announced that the company has been invited to present at the 2015 Defense Innovation Challenge in Austin, Texas on “Rapid identification […]
Los Angeles, CA – June 1st, 2015 – GeneFluidics Inc., a biomedical diagnostics system company, today announced that it has been awarded $3.7 million over five years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development and clinical validation […]
IRWINDALE, CA – January 30, 2013 – GeneFluidics, Inc., a biotech company that designs, markets and manufactures automated testing equipment based on proprietary electrochemical-based molecular analysis and an advanced engineering platform, today announced that it has received ISO 13485:2003 certification, an internationally recognized quality standard for medical devices. The ISO 13485:2003 certification […]
MONTEREY PARK, CA – February 2, 2011 – GeneFluidics, Inc. is pleased to announce a joint publication with Stanford University, University of Arizona, and Veterans Affairs Palo Alto which has made the cover of The Journal of Urology, the Official Journal of the American Urological Association. In this joint publication, […]
IRWINDALE, CA – November 28, 2010 – GeneFluidics, Inc., a biotech company that designs, markets and manufactures automated testing equipment based on proprietary electrochemical-based molecular analysis and an advanced engineering platform, today announced that it has received ISO 9001:2008 certification, an internationally recognized quality system standard for continual improvement to process performance. […]
MONTEREY PARK, CA – March 12, 2009 – GeneFluidics, Inc., a biotech company that designs, markets and manufactures automated testing equipment based on proprietary electrochemical-based molecular analysis and an advanced engineering platform, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), through the National Institutes of Health (NIH) has funded a […]
MONTEREY PARK, CA – January 29, 2009 – GeneFluidics, Inc. is pleased to announce that their Proteus Robotic System has received the New Product Award from the Association for Laboratory Automation (ALA) at LabAutomation2009. The ALA is an international organization devoted to the study, development, and use of laboratory automation. […]
LOS ANGELES, CA – (BusinessWire) – February 2, 2006 – For the millions of people who suffer from urinary tract infections each year and the doctors who treat them, a promising new biosensor technology has been developed that may replace antiquated testing methods and save precious health care dollars. In […]